The Shuman Law Firm Announces Investigation on Behalf of BioForm Medical, Inc. Shareholders

The Shuman Law Firm today announced that it is investigating potential breaches of fiduciary duty and other violations of state law on behalf of shareholders of of BioForm Medical, Inc. (“BioForm Medical” or the “Company”) (Nasdaq: BFRM) related to the Company’s merger agreement with Merz Pharma Group ("Merz"), a privately held company based in Frankfurt, Germany.

The cash transaction is valued at approximately $253 million, based on the Company’s outstanding shares of common stock.

Under the terms of a definitive agreement entered into by the parties, Merz will acquire all of the outstanding shares of BioForm Medical for $5.45 per share in cash pursuant to a cash tender offer followed by a second-step merger. Following completion of the transaction, BioForm Medical will become a wholly-owned subsidiary of Merz and will be renamed Merz Aesthetics. The investigation concerns whether the board breached their fiduciary duties by agreeing to various deal protections that may prevent other superior offers. These protections include restrictions on solicitation of alternative proposals, a top-up option to acquire additional shares, the board’s agreement to pay an $8 million termination fee.

If you are interested in discussing your rights as a BioForm Medical shareholder, or have information relating to this investigation, please contact Kip B. Shuman or Rusty E. Glenn toll free at [phone] or email Mr. Shuman at [e-mail] or Mr. Glenn at [e-mail].

The Shuman Law Firm represents investors throughout the nation, concentrating its practice in securities class actions and shareholder derivative actions.